Top

Published in:

01-12-2008 | Melanomas

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

Authors: Craig L. Slingluff Jr, MD, Galina V. Yamshchikov, MS, Kevin T. Hogan, PhD, Sarah C. Hibbitts, BA, Gina R. Petroni, PhD, Eric A. Bissonette, MS, James W. Patterson, MD, Patrice Y. Neese, MS, William W. Grosh, MD, Kimberly A. Chianese-Bullock, PhD, Andrea Czarkowski, BS, Patrice K. Rehm, MD, Jayashree Parekh, MD

Published in: Annals of Surgical Oncology | Issue 12/2008

Abstract

Background

We hypothesized that lymph nodes draining sites of cutaneous vaccination could be identified by sentinel node biopsy techniques, and that measuring T-cell response with lymphocytes obtained from these lymph nodes would provide a more sensitive measure of immunogenicity than would the same measurement made with peripheral blood lymphocytes (PBL).

Methods

ELISpot analysis was used to determine the magnitude of vaccine-specific T-cell response in the sentinel immunized nodes (SIN), random lymph nodes, and peripheral blood lymphocytes (PBL) obtained from patients enrolled in clinical trials of experimental melanoma vaccines.

Results

The SIN biopsy was successful in 97% of cases and morbidity was very low. The T-cell response to vaccination was detected with greater sensitivity in the SIN (57%) than in PBL (39%), and evaluation of T-cell responses in the SIN and the PBL together yielded T-cell responses in 63% of patients. When the T-cell responses from a SIN and a random lymph node were compared in four patients, immune responses were detected to one of the vaccine peptides in three of these four patients. In all of those cases, responses were present in the SIN but absent from the random lymph node.

Conclusion

Measurements of T-cell responsiveness to cutaneous immunization are more frequently positive in the SIN than they are in the PBL, however evaluation of both the SIN and PBL permit a more sensitive measure of T-cell immunogenicity than use of either single source.

Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909–15PubMedCrossRef

Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90:51–81PubMedCrossRef

Slingluff CL, Chianese-Bullock KA, Bullock TNJ, et al. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Adv Immunol 2006; 90:243–95PubMedCrossRef

Marchand M, van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219–30PubMedCrossRef

Coulie PG, Karanikas V, Colau D, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98:10290–5PubMedCrossRef

Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321–7PubMedCrossRef

Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999; 163:1690–5PubMed

Yamshchikov GV, Barnd DL, Eastham S, et al. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients. Int J Cancer 2001; 92:703–11PubMedCrossRef

Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21:4016–26PubMedCrossRef

10.

Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004; 22:4474–85PubMedCrossRef

11.

Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13:6386–95PubMedCrossRef

12.

Storkus WJ, Salter RD, Cresswell P, et al. Peptide-induced modulation of target cell sensitivity to natural killing. J Immunol 1992; 149:1185–90PubMed

13.

Anderson KS, Alexander J, Wei M, et al. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines. J Immunol 1993; 151:3407–19PubMed

14.

Kittlesen DJ, Thompson LW, Gulden PH, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development. J Immunol 1998; 160:2099–106PubMed

15.

Skipper JC, Hendrickson RC, Gulden PH, et al. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996; 183:527–34PubMedCrossRef

16.

Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264:716–9PubMedCrossRef

17.

Skipper JC, Kittlesen DJ, Hendrickson RC, et al. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 1996; 157:5027–33PubMed

18.

Slingluff CL Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100(280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001; 7:3012–24PubMed

19.

Kawakami Y, Robbins PF, Wang X, et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 1998; 161:6985–92PubMed

20.

Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176:1453–7PubMedCrossRef

21.

Gaugler B, Van den Eynde B, van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179:921–30PubMedCrossRef

22.

Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 1996; 157:2539–48PubMed

23.

Huang LQ, Brasseur F, Serrano A, et al. Cytolytic T lymphocytes recognize an antigen encoded by MAGE-A10 on a human melanoma. J Immunol 1999; 162:6849–54PubMed

24.

Chaux P, Luiten R, Demotte N, et al. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. J Immunol 1999; 163:2928–36PubMed

25.

Wang RF, Johnston SL, Southwood S, et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 1998; 160:890–7PubMed

26.

Renkvist N, Castelli C, Robbins PF, et al. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50:3–15PubMedCrossRef

27.

Blum-Tirouvanziam U, Servis C, Habluetzel A, et al. Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J Immunol 1995; 154:3922–31PubMed

28.

Johnson RP, Trocha A, Yang L, et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J Immunol 1991; 147:1512–21PubMed

29.

Goulder PJ, Sewell AK, Lalloo DG, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997; 185:1423–33PubMedCrossRef

30.

Brander C, Hartman KE, Trocha AK, et al. Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 1998; 101:2559–66PubMedCrossRef

31.

Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355:1307–17PubMedCrossRef

32.

Sondak VK, Zager JS, Messina JL, et al. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol 2007; 5:483–90PubMed

33.

Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy–a common event. Surgery 2001; 130:439–42PubMedCrossRef

34.

Leong SP, Donegan E, Heffernon W, et al. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol 2000; 7:361–6PubMedCrossRef

35.

Macatonia SE, Knight SC, Edwards AJ, et al. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med 1987; 166:1654–67PubMedCrossRef

36.

Rosato A, Zambon A, Macino B, et al. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. Int J Cancer 1996; 65:847–51PubMedCrossRef

37.

Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147:729–37PubMed

Title: Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines
Authors: Craig L. Slingluff Jr, MD
Galina V. Yamshchikov, MS
Kevin T. Hogan, PhD
Sarah C. Hibbitts, BA
Gina R. Petroni, PhD
Eric A. Bissonette, MS
James W. Patterson, MD
Patrice Y. Neese, MS
William W. Grosh, MD
Kimberly A. Chianese-Bullock, PhD
Andrea Czarkowski, BS
Patrice K. Rehm, MD
Jayashree Parekh, MD
Publication date: 01-12-2008
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 12/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-008-0046-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of the Sentinel Immunized Node for Immune Monitoring of Cancer Vaccines

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2008

Feasibility of Sentinel Lymph Node Biopsy Through an Inframammary Incision for a Nipple-Sparing Mastectomy

Disturbed XIAP and XAF1 Expression Balance Is an Independent Prognostic Factor in Gastric Adenocarcinomas

Screening for or Prevention of Local Ipsilateral Recurrence and Contralateral Breast Cancer After Breast-Conserving Surgery?

Lymphovascular Invasion and Lobular Histology are Associated with Increased Incidence of Isolated Tumor Cells in Sentinel Lymph Nodes from Early-Stage Breast Cancer Patients

The Keystone Island and Pedicle Flap: a Handy Local Flap for Soft Tissue Reconstruction

Venous Thromboembolism in Cancer Patients Undergoing Major Surgery